Description
Buy Buprenorphine Powder Online Europe
Product Description.Buy Buprenorphine Powder Online Europe
Buprenorphine is an opioid used to treat dependence/addiction to opioids, acute pain, and chronic pain. Buprenorphine belongs to a class of drugs called mixed opioid agonist-antagonists. It helps prevent withdrawal symptoms caused by stopping other opioids.Buprenorphine HCl is the hydrochloride salt form of buprenorphine, which belongs to the class of organic compounds known as morphinans.Buy Buprenorphine Powder Online Europe Buprenorphine is indicated for the treatment of opioid dependence, moderate to severe pain and peri-operative analgesia. It prevents symptoms of withdrawal from opiates such as heroin and is preferred for the induction phase of treatment (conducted under medical supervision).
It is considered to be better tolerated without naloxone during the first days of treatment. Buprenorphine HCl was approved by the FDA in injectable form in 1981, under the trade name Buprenex. Â In 2002, it was approved in sublingual form under the trade name Subutex. Â Buprenorphine HCl is currently manufactured through large-scale semi-synthetic methods. Semisynthesis, or partial chemical synthesis, employs compounds isolated from natural sources as starting materials.Buy Buprenorphine Powder Online Europe
Find Lowest Prices on
what is Buprenex and how is it used?
Buprenex is a prescription medicine used to treat the symptoms of Moderate-to-Severe Pain. Buprenex may be used alone or with other medications.
Buprenex belongs to a class of drugs called Opioid Analgesics; Analgesics, Opioid Partial Agonist.
It is not known if Buprenex is safe and effective in children younger than 2 years of age.
DOSAGE AND ADMINISTRATION
Adults: The usual dosage for persons 13 years of age and over is 1 ml Buprenex (buprenorphine) (0.3 mg buprenorphine) given by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed. Repeat once (up to 0.3 mg) if required, 30 to 60 minutes after initial dosage, giving consideration to previous dose pharmacokinetics, and thereafter only as needed. In high-risk patients (e.g., elderly, debilitated, presence of respiratory disease, etc.) and/or in patients where other CNS depressants are present, such as in the immediate postoperative period, the dose should be reduced by approximately one-half. Extra caution should be exercised with the intravenous route of administration, particularly with the initial dose.
Occasionally, it may be necessary to administer single doses of up to 0.6 mg to adults depending on the severity of the pain and the response of the patient. This dose should only be given I.M. and only to adult patients who are not in a high risk category . At this time, there are insufficient data to recommend single doses greater than 0.6 mg for long-term use.
Children: Buprenex (buprenorphine) has been used in children 2-12 years of age at doses between 2-6 micrograms/kg of body weight given every 4-6 hours. There is insufficient experience to recommend a dose in infants below the age of two years, single doses greater than 6 micrograms/kg of body weight, or the use of a repeat or second dose at 30-60 minutes (such as is used in adults). Since there is some evidence that not all children clear buprenorphine faster than adults, fixed interval or “round-the-clock” dosing should not be undertaken until the proper inter-dose interval has been established by clinical observation of the child. Physicians should recognize that, as with adults, some pediatric patients may not need to be remedicated for 6-8 hours.buy magic mushrooms online europe
Safety and Handling: Buprenex (buprenorphine) is supplied in sealed ampules and poses no known environmental risk to health care providers. Accidental dermal exposure should be treated by removal of any contaminated clothing and rinsing the affected area with water.
Buprenex (buprenorphine) is a potent narcotic, and like all drugs of this class has been associated with abuse and dependence among health care providers. To control the risk of diversion, it is recommended that measures appropriate to the health care setting be taken to provide rigid accounting, control of wastage, and restriction of access.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Maximum pain relief is generally within an hour with effects up to 24 hours.
Product Name: Buprenorphine
Cas No: 52485-79-7
Formula: C29H41NO4
Appearance: White powder
Purity: above 98.5%
Reviews
There are no reviews yet.